drugset
drugset / Trial / NCT04936841

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

NCT04936841 ↗

Phase 2 Terminated 5 enrolled University of Wisconsin, Madison Nektar Therapeutics · collab
NaSingle-groupOpen-labelTreatment

Summary

This trial will evaluate safety and efficacy of the combination of anti-PD1, NKTR-214, and palliative radiation therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Twenty-four participants will be enrolled to evaluate the efficacy of this combination.

Timeline

Start
2021-08-05
Primary completion
2022-10-04
Completion
2022-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bempegaldesleukin Protein / enzyme biologic 0.006 mg/kg Intravenous
Subject Pembrolizumab Monoclonal antibody 200 mg —

Indications

head and neck squamous cell carcinoma